Ida Aronchik

1.7k total citations
31 papers, 981 citations indexed

About

Ida Aronchik is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, Ida Aronchik has authored 31 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Toxicology. Recurrent topics in Ida Aronchik's work include Genomics, phytochemicals, and oxidative stress (6 papers), Melanoma and MAPK Pathways (5 papers) and Bioactive Compounds and Antitumor Agents (4 papers). Ida Aronchik is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (6 papers), Melanoma and MAPK Pathways (5 papers) and Bioactive Compounds and Antitumor Agents (4 papers). Ida Aronchik collaborates with scholars based in United States, Spain and Italy. Ida Aronchik's co-authors include Gary L. Firestone, Theodora M. Mauro, Leonard F. Bjeldanes, Martin J. Behne, Graham Bench, Ervin H. Epstein, Tullio Pozzan, Peter M. Elias, Hui Cen and Christine Taylor Brew and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer.

In The Last Decade

Ida Aronchik

30 papers receiving 963 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ida Aronchik United States	18	670	187	155	138	115	31	981
Pasarat Khongkow Thailand	14	823 1.2×	66 0.4×	246 1.6×	37 0.3×	141 1.2×	27	1.2k
Fernanda Faião‐Flores Brazil	18	480 0.7×	102 0.5×	158 1.0×	25 0.2×	146 1.3×	32	860
Majken Westergaard Denmark	11	708 1.1×	106 0.6×	185 1.2×	53 0.4×	58 0.5×	14	1.0k
Werner Bollag Switzerland	14	918 1.4×	126 0.7×	157 1.0×	263 1.9×	104 0.9×	25	1.2k
Barry J. Maurer United States	17	1.0k 1.5×	20 0.1×	164 1.1×	84 0.6×	128 1.1×	40	1.3k
Α. Φωτίου United Kingdom	14	339 0.5×	137 0.7×	208 1.3×	99 0.7×	114 1.0×	23	755
Marianna G. Yakubovskaya Russia	18	572 0.9×	30 0.2×	143 0.9×	95 0.7×	18 0.2×	83	863
Anne‐Marie Mus Netherlands	6	299 0.4×	855 4.6×	268 1.7×	31 0.2×	29 0.3×	6	1.8k
Shuxi Qiao United States	16	597 0.9×	66 0.4×	101 0.7×	23 0.2×	88 0.8×	18	975
Claudia Buerger Germany	14	514 0.8×	169 0.9×	172 1.1×	25 0.2×	138 1.2×	25	929

Countries citing papers authored by Ida Aronchik

Since Specialization

Citations

This map shows the geographic impact of Ida Aronchik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ida Aronchik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ida Aronchik more than expected).

Fields of papers citing papers by Ida Aronchik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ida Aronchik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ida Aronchik. The network helps show where Ida Aronchik may publish in the future.

Co-authorship network of co-authors of Ida Aronchik

This figure shows the co-authorship network connecting the top 25 collaborators of Ida Aronchik. A scholar is included among the top collaborators of Ida Aronchik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ida Aronchik. Ida Aronchik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Solanki, Hitendra S., Yu Chi Yang, Ida Aronchik, et al.. (2025). In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRAS G12C-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 31(6). 1150–1162.

Hollebecque, Antoine, Stefania Salvagni, Ruth Plummer, et al.. (2022). Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 128(17). 3185–3195. 32 indexed citations

Hollebecque, Antoine, Johann S. de Bono, Stefania Salvagni, et al.. (2021). 7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology. 32. S4–S4. 1 indexed citations

Hollebecque, Antoine, Johann S. de Bono, Stefania Salvagni, et al.. (2020). 18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study. Annals of Oncology. 31. S6–S6. 3 indexed citations

Moreno, Víctor, Irene Braña, Juan Manuel Sepúlveda-Sánchez, et al.. (2020). 527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study. Annals of Oncology. 31. S463–S464. 1 indexed citations

Paz‐Ares, Luis, Óscar Juan, Enric Carcereny, et al.. (2020). 559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC). Annals of Oncology. 31. S482–S483. 2 indexed citations

Moreno, Víctor, Irene Braña, Juan Manuel Sepúlveda-Sánchez, et al.. (2020). 16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology. 31. S5–S5. 3 indexed citations

Moreno, Víctor, Juan Manuel Sepúlveda-Sánchez, María Vieito, et al.. (2020). Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Annals of Oncology. 31(6). 780–788. 50 indexed citations

Aronchik, Ida, Yumin Dai, Carmen Barnes, et al.. (2018). Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. Molecular Cancer Research. 17(2). 642–654. 26 indexed citations

10.

Aronchik, Ida, et al.. (2016). Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells. Cell Biology and Toxicology. 32(2). 103–119. 12 indexed citations

11.

Durkin, Kathleen A., et al.. (2016). Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells. Biochemical Pharmacology. 127. 13–27. 59 indexed citations

12.

Aronchik, Ida, B.A. Appleton, Stephen E. Basham, et al.. (2014). Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers. Molecular Cancer Research. 12(5). 803–812. 61 indexed citations

13.

Aronchik, Ida, et al.. (2014). The Antiproliferative Response of Indole-3-Carbinol in Human Melanoma Cells Is Triggered by an Interaction with NEDD4-1 and Disruption of Wild-Type PTEN Degradation. Molecular Cancer Research. 12(11). 1621–1634. 60 indexed citations

14.

Costales, Abran, Savithri Ramurthy, Jiong Lan, et al.. (2014). 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(6). 1592–1596. 24 indexed citations

15.

Aronchik, Ida, Tony Chen, Kathleen A. Durkin, et al.. (2011). Target protein interactions of indole‐3‐carbinol and the highly potent derivative 1‐benzyl‐I3C with the C‐terminal domain of human elastase uncouples cell cycle arrest from apoptotic signaling. Molecular Carcinogenesis. 51(11). 881–894. 12 indexed citations

16.

Aronchik, Ida, Leonard F. Bjeldanes, & Gary L. Firestone. (2010). Direct Inhibition of Elastase Activity by Indole-3-Carbinol Triggers a CD40-TRAF Regulatory Cascade That Disrupts NF-κB Transcriptional Activity in Human Breast Cancer Cells. Cancer Research. 70(12). 4961–4971. 30 indexed citations

17.

Hachem, Jean Pierre, Martin J. Behne, Ida Aronchik, et al.. (2005). Extracellular pH Controls NHE1 Expression in Epidermis and Keratinocytes: Implications for Barrier Repair. Journal of Investigative Dermatology. 125(4). 790–797. 49 indexed citations

18.

Behne, Martin J., Chia‐Ling Tu, Ida Aronchik, et al.. (2003). Human Keratinocyte ATP2C1 Localizes to the Golgi and Controls Golgi Ca2+ Stores. Journal of Investigative Dermatology. 121(4). 688–694. 110 indexed citations

19.

Aronchik, Ida, Martin J. Behne, Debbie Crumrine, et al.. (2003). Actin Reorganization Is Abnormal and Cellular ATP Is Decreased in Hailey-Hailey Keratinocytes. Journal of Investigative Dermatology. 121(4). 681–687. 32 indexed citations

20.

Behne, Martin J., Nicholas P. Barry, Kerry M. Hanson, et al.. (2003). Neonatal Development of the Stratum Corneum pH Gradient: Localization and Mechanisms Leading to Emergence of Optimal Barrier Function. Journal of Investigative Dermatology. 120(6). 998–1006. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact